Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study

Abstract Background Berotralstat (BCX7353) is an oral, once‐daily inhibitor of plasma kallikrein recently approved for prevention of angioedema attacks in adults and adolescents with hereditary angioedema (HAE). The objective of this report is to summarize results from an interim analysis of an ongo...

全面介紹

書目詳細資料

Principais autores:	Henriette Farkas, Marcin Stobiecki, Jonny Peter, Tamar Kinaciyan, Marcus Maurer, Emel Aygören‐Pürsün, Sorena Kiani‐Alikhan, Adrian Wu, Avner Reshef, Anette Bygum, Olivier Fain, David Hagin, Aarnoud Huissoon, Miloš Jeseňák, Karen Lindsay, Vesna Grivcheva Panovska, Urs C. Steiner, Celia Zubrinich, Jessica M. Best, Melanie Cornpropst, Daniel Dix, Sylvia M. Dobo, Heather A. Iocca, Bhavisha Desai, Sharon C. Murray, Eniko Nagy, William P. Sheridan
格式:	Artigo
語言:	Inglês
出版:	Wiley 2021-06-01
叢編:	Clinical and Translational Allergy
主題:	berotralstat hereditary angioedema long‐term prophylaxis safety
在線閱讀:	https://doi.org/10.1002/clt2.12035
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!